NEW YORK — Akeso Inc. (SEHK:9926) is rapidly advancing its clinical oncology profile as it prepares to showcase a substantial pipeline at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid. The Hong Kong–listed biopharma’s upcoming presentations—featuring nearly 30 clinical studies, including 12 focused on its lead bispecific antibody ivonescimab—highlight a pivotal transition point for the company: evolving from a development-stage player toward a commercially active oncology business. Ivonescimab’s Phase III data in biliary tract cancer and non-small-cell lung cancer (NSCLC), coupled with growing commercial traction in China, has drawn heightened investor attention, intensifying scrutiny of the company’s valuation premium amid a competitive landscape that includes established players such as Merck & Co. (NYSE:MRK), AstraZeneca (NASDAQ:AZN), and Roche (OTCQX:RHHBY).
Akeso’s upcoming ESMO 2026 engagement reflects progress on multiple fronts, from clinical evidence to market positioning. The Phase III HARMONi-GI1 trial in first-line advanced biliary tract cancer met its primary overall survival endpoint and key secondary measures, establishing ivonescimab plus chemotherapy as an efficacy alternative to AstraZeneca’s durvalumab-based regimen. Selected as a late-breaking abstract for the Congress’s Presidential Symposium, these results underscore the potential clinical relevance of Akeso’s bispecific approach in a tumor type with historically limited treatment options. Meanwhile, HARMONi-2, a pivotal trial comparing ivonescimab with Merck’s pembrolizumab in PD-L1-positive NSCLC, reported a statistically significant overall survival benefit at the interim analysis, positioning ivonescimab as a notable contender against industry-leading PD-1 checkpoint inhibitors.
These Phase III milestones arrive as Akeso expands its commercial footprint, reporting RMB1.8 billion (approximately US$250 million) in first-half 2026 sales—reflecting a 28.7% year-over-year increase—and maintaining robust cash reserves above RMB9 billion to support ongoing operations. The inclusion of five self-developed innovative drugs within China’s National Reimbursement Drug List by end-2025 signals improved reimbursement access that could bolster market penetration. Importantly, China’s recent drug regulatory nod for ivonescimab plus chemotherapy as a first-line treatment for squamous NSCLC adds a pivotal commercial indication and highlights regulatory momentum within the country’s increasingly critical oncology market.
Yet this rapid clinical and commercial expansion fuels debate around Akeso’s premium valuation multiples. According to third-party analysis by Simply Wall St, the stock last closed near HK$97.50, reflecting a 90-day return of 14.1% but a year-to-date loss of nearly 14%. The company’s price-to-sales multiple stands around 22.3x—substantially above the 10.6x average for Hong Kong biotech peers and well beyond the cited “fair” ratio of 13.4x. These figures underscore a degree of optimism priced in by investors anticipating successful ESMO readouts and future regulatory or market execution. The core investor question is no longer whether Akeso’s clinical achievements are priced into the stock but what concrete near-term catalysts can justify sustaining or expanding current multiples amid competitive headwinds.
Contextualizing Akeso’s trajectory against large-cap oncology benchmarks clarifies the challenges ahead. Merck’s Keytruda remains the PD-1 checkpoint inhibitor standard, delivered on a global scale with extensive indications. While HARMONi-2’s interim data show ivonescimab’s promising survival gains versus pembrolizumab in select NSCLC patients, Merck’s broad commercial infrastructure and pipeline diversification create high barriers for emerging players. Similarly, AstraZeneca’s multi-indication oncology franchise leverages durvalumab (Imfinzi) across tumors, with the HARMONi-GI1 trial representing a critical but single strategic contest in biliary tract cancer. Roche’s diversified portfolio, spanning antibodies, targeted agents, and diagnostics, highlights the contrast with Akeso’s narrower current asset base heavily reliant on expanding ivonescimab and cadonilimab’s clinical success.
Institutional positioning in oncology equities has recently favored companies demonstrating both late-stage data and scaling commercial capabilities, particularly as insurers and payers demand clear clinical advantage coupled with market access efficiency. Akeso’s reported Chinese NRDL inclusions and regulatory approvals indicate constructive reimbursement and regulatory alignment, a vital factor for sustaining revenue growth in a highly cost-conscious environment. The company’s cash position offers runway flexibility amid global economic uncertainties and capital market volatility, supporting ongoing development and potential geographic expansion.
Looking ahead, ESMO 2026 will serve as a critical event for Akeso to validate clinical momentum with peer-reviewed data, shaping investor sentiment and institutional positioning. The degree to which ivonescimab’s Phase III results can be corroborated in broader patient populations and the speed of regulatory approvals outside China will influence capital flows into the stock and the company’s ability to convert trial successes into sustainable revenues. Broader macroeconomic factors—including evolving healthcare policies in China, global supply chain dynamics for biologics, and ongoing competitive pressures from entrenched PD-(L)1 therapies—will further inform valuation and strategic execution.
Akeso’s advancing pipeline and commercial achievements position it as one of the most closely watched emerging oncology companies in Asia, but its future will depend on translating clinical data into durable market share gains amid stiff competition and heightened investor scrutiny. The interplay of approved indications, reimbursement frameworks, and later-stage trial results will be decisive in defining whether ivonescimab and related assets can establish a sustainable commercial foothold comparable to the diversified oncology giants.
Sources:
Akeso News, “Nearly 30 Clinical Studies to be Presented at ESMO 2026” (September 22, 2026)
https://akesobio.com/cn/media/akeso-news/20260922-1/
Akeso News, “Phase III HARMONi-GI1 Trial Toplines” (August 26, 2026)
https://akesobio.com/en/media/akeso-news/260826/
Akeso News, “HARMONi-2 Trial Interim Analysis” (September 3, 2026)
https://akesobio.com/en/media/akeso-news/260903/
Akeso News, “2026 Interim Financials” (August 28, 2026)
https://akesobio.com/en/media/akeso-news/260828/
Simply Wall St, “Akeso Valuation and Share Price Analysis” (September 23, 2026)
https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-after-esmo-trial-spotlight-is-the-oncology-up
Spotrate NewsDesk
